<DOC>
	<DOCNO>NCT00255281</DOCNO>
	<brief_summary>The current study design assess efficacy safety iv AZD7009 conversion AF</brief_summary>
	<brief_title>Efficacy Safety AZD7009 Treatment Atrial Fibrillation</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<criteria>Clinical indication cardioversion Atrial Fibrillation . Effective oral anticoagulation accord local routine TEE without find intracardial thrombus sign thrombogenecity Clinically significant sinus and/or AV node dysfunction . Serum plasma potassium &lt; 3.8 mmol/L &gt; 5.0 mmol/L . QTc ( Bazett ) &gt; 450 ms. Any QRS duration &gt; 150 m</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2007</verification_date>
</DOC>